Overview

Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The incidence of efficacy failure at 12 months between two regimens.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Sirolimus